BCNA News 01 Apr 2020
Kadcyla added to PBS for early breast cancer
The breast cancer drug Kadcyla (trastuzumab emtansine) has been listed on the Pharmaceutical Benefits Scheme (PBS) today (1 April 2020) for the adjuvant (after surgery) treatment of HER2-positive early breast cancer.
Kadcyla will be available through the PBS for women and men who have residual (remaining) disease after neoadjuvant (before surgery) treatment with HER2 targeted therapy. An international clinical trial (KATHERINE) found that having Kadcyla after breast cancer surgery reduced the risk of recurrence of invasive breast cancer or of dying by 50 per cent, compared with current standard treatment, Herceptin (trastuzumab).
Breast Cancer Network Australia provided a submission in support of listing Kadcyla on the PBS and welcomes today’s announcement.
PBS listing means eligible people will be able to access Kadcyla for the cost of a script fee ($41.00 or $6.60 for concession card holders).
For information about whether Kadcyla might be an appropriate treatment for you, please talk to a member of your treating team.